Ep166: Chris Garcia on Engineering Protein Drugs for Cancer, Autoimmunity

Episode Summary

Executive Summary: Chris Garcia recounts his path from a would-be tennis pro to a leading structural immunologist at Stanford and HHMI investigator, showing how injury, curiosity, and discipline redirected him toward science. He explains how structural biology revealed the mechanics of immune recognition, how that work translated into biotech and therapeutics, and why running and long-term thinking shape both his life and research strategy.

Main Topics: From tennis ambition to scientific vocation (Priority: 5/5): Garcia describes early plans to become a professional tennis player, his disappointment at Tulane, and a severe rugby neck injury that forced a reinvention and pushed him fully into academics and science. Discovery of chemistry and structural biology (Priority: 5/5): He explains how advanced organic chemistry and then the MHC structure transformed his understanding, convincing him that visualizing molecular structure was the key to understanding biology. Graduate training and Genentech as a formative bridge (Priority: 5/5): At Johns Hopkins and then Genentech, Garcia built the technical foundation in recombinant protein expression and protein engineering that later enabled his T-cell receptor and cytokine work. Solving the T-cell receptor/MHC structure (Priority: 5/5): He recounts the international race to determine TCR-peptide-MHC structure, why it mattered for understanding self vs. non-self recognition, and how his group succeeded at Scripps and Stanford. Translation to biotech and cytokine engineering (Priority: 5/5): Garcia discusses moving from basic structural immunology to company-building, especially cytokine design and IL-2 engineering through Synthokine, and the broader promise of engineered immune proteins as drugs. Ultra-running as a scientific engine (Priority: 4/5): Running is presented not as a hobby but as a core cognitive practice that supports clarity, creativity, emotional balance, and long-term scientific productivity. Choosing important and interesting problems (Priority: 5/5): Garcia lays out his framework for selecting scientific questions, emphasizing long half-life, first-principles work, and avoiding seductive but low-value projects.

Key Arguments: A serious scientific career can emerge from reinvention after failure or injury; Garcia’s neck injury became the turning point that made him disciplined and academically focused. Structural biology is uniquely powerful because it turns abstract biological processes into visible mechanisms, enabling both understanding and engineering. Training in both chemistry and biology gave Garcia an unusual perspective that helped him tackle protein engineering and immune receptor problems. Genentech’s tools and culture gave him practical mastery of recombinant proteins and protein engineering that academic labs then lacked. The T-cell receptor/MHC structure was a foundational problem because it underlies immune discrimination between self and foreign and remains central to cancer immunotherapy. Cytokines are powerful but are not naturally optimized as drugs; they require engineering to become safe, selective, and clinically useful. Ultra-running improves Garcia’s science by creating time for deep thought, integrating ideas, and helping him sustain a long-view approach to research. The best science targets problems that are both important and interesting; otherwise, researchers risk wasting effort on intellectually seductive but low-impact work. AI and diffusion-based protein design may become increasingly valuable, but Garcia still values first-principles engineering and is cautiously optimistic. Scientists should pivot before a field becomes overcrowded or declines, rather than staying too long after the peak has passed.

Data Points: Years at Scripps: almost 6 years - Garcia spent nearly six years at Scripps doing the TCR/MHC structural work before moving to Stanford. Time at Genentech: about 2.5 years - He trained there in recombinant protein expression and protein engineering before returning to academia. First 10 years of Stanford lab: about 10 years - He describes the first decade of his Stanford lab as primarily building structural blueprints before heavier translation. Running routine: 25–30 mile Saturday morning long runs - Garcia says he has done long Saturday runs for years as part of his ultra training. ULTRA experience: 24 years - He says he has been doing ultra running since starting at Stanford and is still active decades later. Company count: 8 or 9 companies - He notes that he is founder or co-founder of roughly eight or nine companies across different technology areas. IL-2 clinical issue: can be 'almost lethally toxic' - He explains why unmodified IL-2 has been hard to use as a cancer therapy despite its potency. Super-2 and later IL-2 variants: engineered in 2005; partial agonists around 2018 - He references the initial IL-2 receptor complex structure work and later design of partial agonists. TCR race: worldwide race to crack the structure - He emphasizes the competitive urgency around solving the T-cell receptor/MHC complex. Student publication output: 2 Science papers - Garcia notes he published two Science papers as a graduate student in Mario Amzel’s lab.

Pivotal Quotes: "the complete mystery of this complicated biological phenomenon was completely resolved" — Chris Garcia: Describing his first reaction to seeing the MHC structure and realizing structure could explain immune recognition. "I can outwork and out suffer anybody" — Chris Garcia: He explains his competitive edge during the race to solve the TCR/MHC structure. "the best protein engineer alive" — Luke Timmerman quoting Aaron Ring: A compliment cited in the introduction to convey Garcia’s reputation in the field.

Implications: Garcia’s story shows how structural biology can drive drug discovery, especially in immunology. His work suggests the future lies in engineered cytokines, smarter immune therapies, and AI-assisted protein design—guided by rigorous first-principles thinking.